Lv4
428 积分 2022-09-19 加入
埃万妥单抗临床使用及不良反应管理专家共识（2025版）
4天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
29天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
29天前
已完结
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
1个月前
已完结
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
1个月前
已完结
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
1个月前
已完结
Circulating tumor DNA as a biomarker in early phase clinical trials
1个月前
已完结
An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO Value-Based Radiation Oncology framework
1个月前
已完结
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung – An AIO phase Ib/II trial
1个月前
已关闭
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
